Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 12 of the 44 sources its claims cite were checked for support.

Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial

Open access
Abbar, Mocrane, Demattei, Christophe, El-Hage, Wissam, Llorca, Pierre-Michel, Samalin, Ludovic, Demaricourt, Pierre, Gaillard, Raphael, Courtet, Philippe, Vaiva, Guillaume, Gorwood, Philip, Fabbro, Pascale, Jollant, Fabrice·2022·BMJ

Abstract

Objective: To confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks, overall and according to diagnostic group. Design: Prospective, double blind, superiority, randomised placebo controlled trial. Setting: Seven French teaching hospitals between 13 April 2015 and 12 March 2019. Eligibility criteria for participants: Aged 18 or older with current suicidal ideation, admitted to hospital voluntarily. Exclusion criteria included a history of schizophrenia or other psychotic disorders, substance dependence, and contraindications for ketamine. Participants: 156 participants were recruited and randomised to placebo (n=83) or ketamine (n=73), stratified by centre and diagnosis: bipolar, depressive, or other disorders. Intervention: Two 40 minute intravenous infusions of ketamine (0.5 mg/kg) or placebo (saline) were administered at baseline and 24 hours, in addition to usual treatment. Main outcome measures: The primary outcome was the rate of patients in full suicidal remission at day 3, according to the scale for suicidal ideation total score ≤3. Analyses were conducted on an intention-to-treat basis. Results: More participants receiving ketamine reached full remission of suicidal ideas at day 3 than those receiving placebo: 46 (63.0%) of 83 participants in the ketamine arm and 25 (31.6%) of 73 in the placebo arm (odds ratio 3.7 (95% confidence interval 1.9 to 7.3), P<0.001). This effect differed according to the diagnosis (treatment: P<0.001; interaction: P=0.02): bipolar (odds ratio 14.1 (95% confidence interval 3.0 to 92.2), P<0.001), depressive (1.3 (0.3 to 5.2), P=0.6), or other disorders (3.7 (0.9 to 17.3, P=0.07)). Side effects were limited. No manic or psychotic symptom was seen. Moreover, a mediating effect of mental pain was found. At week 6, remission in the ketamine arm remained high, although non-significantly versus placebo (69.5% v 56.3%; odds ratio 0.8 (95% confidence interval 0.3 to 2.5), P=0.7). Conclusions: The findings indicate that ketamine is rapid, safe in the short term, and has persistent benefits for acute care in suicidal patients. Comorbid mental disorders appear to be important moderators. An analgesic effect on mental pain might explain the anti-suicidal effects of ketamine. Trial registration: ClinicalTrials.gov NCT02299440 .

Overview

CoChat Summary

TL;DR

In this double-blind randomised placebo-controlled trial, two intravenous ketamine infusions (0.5 mg/kg) rapidly increased full remission of severe suicidal ideation at day 3 compared with saline in voluntarily hospitalised adults. The effect differed by diagnostic group, was strongest in bipolar disorder, and was not statistically significant versus placebo at week 6.

Key findings

  • At day 3, full suicidal remission (clinician-rated SSI total score ≤3) occurred in 46 (63.0%) of 73 patients in the ketamine arm versus 25 (31.6%) of 79 patients with data in the placebo arm (odds ratio 3.7, 95% confidence interval 1.9 to 7.3, P<0.001).
  • The treatment effect differed by diagnosis (interaction P=0.02 or P=0.03 in adjusted analysis): bipolar disorder odds ratio 14.1 (3.0 to 92.2), P<0.001; depressive disorder 1.3 (0.3 to 5.2), P=0.6; other diagnoses 3.7 (0.9 to 17.3), P=0.07.
  • At week 6, remission remained higher in the ketamine arm but was non-significant versus placebo: 69.5% v 56.3%; odds ratio 0.8 (0.3 to 2.5), P=0.7.
  • Side effects were limited: 17 (23.3%) ketamine patients versus 7 (8.4%) placebo patients experienced at least one side effect; common ketamine side effects were sedation (11.0%), depersonalisation (9.6%), and nausea (6.8%). No manic or psychotic symptoms were seen. A mediation analysis suggested the anti-suicidal effect was mediated by reduced psychological pain.

Methods

  • Prospective, double-blind, superiority, randomised placebo-controlled trial conducted in seven French teaching hospitals between 13 April 2015 and 12 March 2019; 156 adults aged ≥18 with current suicidal ideation, voluntarily admitted, were randomised 1:1 to ketamine (n=73) or placebo (n=83), stratified by centre and diagnosis (bipolar, depressive, or other).
  • Intervention: two 40-minute intravenous infusions of ketamine (0.5 mg/kg) or placebo (0.9% saline) at baseline and 24 hours, in addition to usual treatment.
  • Primary outcome: rate of full suicidal remission at day 3, defined as clinician-rated SSI total score ≤3; intention-to-treat analysis used logistic regression with arm-by-diagnostic-group interaction, Holm correction, linear mixed models for secondary outcomes, and a mediation model for psychological pain.

Limitations

  • The paper states that diagnostic-group analyses used smaller samples, which may explain the large effect size in bipolar disorder and the lack of significant difference in depressive disorders; masking may have been compromised because ketamine can induce recognisable effects such as depersonalisation and dizziness, though this was not formally measured; and rapid resolution of suicidal ideas does not equate to reduced risk of suicidal acts, with similar suicide attempt rates during follow-up and potential for ketamine abuse requiring longer follow-up.
  • Evident from the text: one centre included 75.0% of all patients, which may limit generalisability.
  • Evident from the text: the abstract reports ketamine n=83 and placebo n=73, whereas the Methods and Results report ketamine n=73 and placebo n=83; the day 3 placebo denominator is also reported as 79 in the Results.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmj-2021-067194

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC BY-NC · PubMed Central
Fig 1 Trial profile
Fig 1 Trial profileCC BY-NC · PubMed Central
Fig 2 Change in rates of suicidal remission over time within 72 hours of the first injection. Here, suicidal remission corresponds to a score < 3 on the Beck scale for suicidal ideation, clinician rated version
Fig 2 Change in rates of suicidal remission over time within 72 hours of the first injection. Here, suicidal remission corresponds to a score < 3 on the Beck scale for suicidal ideation, clinician rated versionCC BY-NC · PubMed Central
Fig 3 Change in rates of suicidal remission over time within 6 weeks of the first injection. Here, suicidal remission corresponds to a score < 3 on the Beck scale for suicidal ideation, clinician rated version
Fig 3 Change in rates of suicidal remission over time within 6 weeks of the first injection. Here, suicidal remission corresponds to a score < 3 on the Beck scale for suicidal ideation, clinician rated versionCC BY-NC · PubMed Central

Verification

Claims the paper makes

8 Valid · 2 Not valid · 22 Not checked · 80 Own results and interpretations

52 more claims

Create a free account to see all 112 claims and to verify the 32 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 34
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 37 references

Cited by

See all 187

Metadata

Authors
Abbar, M., Demattei, C., El-Hage, W., Llorca, P.-M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P., Fabbro, P., & Jollant, F.
Affiliations
  • Université de Montpellier (FR)
  • Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, CHU Nîmes, University of Montpellier, Nîmes, France
  • CHRU Tours, Research Unit (UMR) 1253, iBrain, University of Tours, National Institute for Health and Medical Research (INSERM), Tours, France
  • Institut Pascal (FR)
  • School of Medicine, University of Paris and Sainte-Anne Hospital, Paris, France
  • Inserm (FR)
  • Department of Psychiatry, CHU Lille, Lille, France
  • Université Paris Cité (FR)
Corresponding author
Jollant, Fabrice
Venue
BMJ
Publisher
BMJ
Published
2022-02-02
Volume
376
Pages
e067194
ISSN
1756-1833 (ISSN-L)
OpenAlex
W4210782512
Cited by
181
References
37
Citations by year
2026: 37 · 2025: 37 · 2024: 46 · 2023: 38 · 2022: 23
FWCI
21.54
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
ketamine, suicidal ideation, suicide prevention, rapid-acting antidepressants, bipolar disorder, depression, psychological suffering, mediating effect, intravenous infusion, hospitalized patients, treatment-resistant depression, mood stabilizers
MeSH terms
Adolescent, Adult, Aged, Analgesics, Depression, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Prospective Studies, Remission Induction, Young Adult, Suicidal Ideation, Patient Acuity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. https://app.cochat.ai/papers/10.1136/bmj-2021-067194
The paper
Abbar, M., Demattei, C., El-Hage, W., Llorca, P.-M., Samalin, L., Demaricourt, P., Gaillard, R., Courtet, P., Vaiva, G., Gorwood, P., Fabbro, P., & Jollant, F. (2022). Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. https://doi.org/10.1136/bmj-2021-067194

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.